Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 19 Oct 16

Research and Markets has announced the addition of the "Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016" report to their offering.

Growth Hormone Secretagogue Receptor Type 1 pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by Companies and remaining by the Universities Institutes.

Growth Hormone Secretagogue Receptor Type 1 Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

'Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2016' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Growth Hormone Secretagogue Receptor Type 1 Overview
  3. Therapeutics Development
  4. Pipeline Products for Growth Hormone Secretagogue Receptor Type 1 - Overview
  5. Pipeline Products for Growth Hormone Secretagogue Receptor Type 1 - Comparative Analysis
  6. Growth Hormone Secretagogue Receptor Type 1 - Therapeutics under Development by Companies
  7. Growth Hormone Secretagogue Receptor Type 1 - Therapeutics under Investigation by Universities/Institutes
  8. Growth Hormone Secretagogue Receptor Type 1 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Growth Hormone Secretagogue Receptor Type 1 - Products under Development by Companies
  13. Growth Hormone Secretagogue Receptor Type 1 - Products under Investigation by Universities/Institutes
  14. Growth Hormone Secretagogue Receptor Type 1 - Companies Involved in Therapeutics Development
  • Aeterna Zentaris Inc.
  • Alize Pharma SAS
  • AstraZeneca Plc
  • Asubio Pharma Co., Ltd.
  • Motus Therapeutics Inc
  • Pfizer Inc.
  • RaQualia Pharma Inc.

For more information about this report visit http://www.researchandmarkets.com/research/m64nts/growth_hormone

View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005653/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.